Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

<p>Abstract</p> <p>Background</p> <p>Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) significantly reduces the relapse rate and disability progression, and improves health-related quality of life (HRQoL), in patients with relapsing-remitting multiple scleros...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Stephenson Judith J, Kern David M, Agarwal Sonalee S, Zeidman Ruth, Rajagopalan Krithika, Kamat Siddhesh A, Foley John
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2012-12-01
Edice:Health and Quality of Life Outcomes
Témata:
Cognitive function
Health-related quality of life
Multiple sclerosis
Natalizumab
Patient-reported outcomes
On-line přístup:http://www.hqlo.com/content/10/1/155
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky